^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    paclitaxel trevatide (ANG1005)

    i
    Other names: GRN1005, ANG1005
    Associations

    News

    Trials
    Company:
    Angiochem
    Drug class:
    Bcl2 inhibitor, Tubulin inhibitor, Lipoprotein receptor agonist
    Related drugs:
    Associations

    News

    Trials
    5ms
    Pharmacotherapy for leptomeningeal disease in breast cancer. (PubMed, Cancer Treat Rev)
    Systemic therapies under investigation for LMD in breast cancer include tucatinib, trastuzumab deruxtecan, and paclitaxel trevatide; trastuzumab is the main intrathecal agent currently under investigation. Large retrospective cohorts with various inclusion criteria and treatment regimens provide some real-world data. However, there remains an urgent need for randomised clinical trials which include patients with LMD across all breast cancer subtypes.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR positive
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib) • paclitaxel trevatide (ANG1005)
    1year
    ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Angiochem Inc | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • paclitaxel trevatide (ANG1005)
    2years
    ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Angiochem Inc | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • paclitaxel trevatide (ANG1005)
    2years
    ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Angiochem Inc | Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Jun 2023 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • paclitaxel trevatide (ANG1005)
    over2years
    ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Angiochem Inc | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Jun 2023
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • paclitaxel trevatide (ANG1005)
    almost3years
    ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Angiochem Inc | Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Mar 2023
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • paclitaxel trevatide (ANG1005)
    3years
    ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Angiochem Inc | Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: Aug 2022 --> Dec 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • paclitaxel trevatide (ANG1005)
    almost4years
    ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Angiochem Inc | Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Jun 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • paclitaxel trevatide (ANG1005)
    4years
    ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Angiochem Inc | Trial completion date: Jul 2022 --> Dec 2022 | Trial primary completion date: Oct 2021 --> Mar 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • paclitaxel trevatide (ANG1005)
    over4years
    Nanotechnology, in silico and endocrine-based strategy for delivering paclitaxel and miRNA: Prospects for the therapeutic management of breast cancer. (PubMed, Semin Cancer Biol)
    miRNA delivery to a specific target site, the development of paclitaxel and miRNA formulations, and nanotechnological strategies for the delivery of nanopaclitaxel in the management of breast cancer are discussed...An in silico analysis revealed that ANG1005 and Abraxane nanoformulations have superior and significantly enhanced interactions with the proteins α-tubulin and Bcl-2...miRNAs can revert abnormal gene expression to normalcy; since miRNAs serve as tumor suppressors. Therefore, restoration of particular miRNAs levels as a replacement therapy may be an effective endocrine potential strategy for treating ER positive/ negative breast cancers.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    albumin-bound paclitaxel • NanoPac (paclitaxel nanoformulation) • paclitaxel trevatide (ANG1005)